1. Market Research
  2. > Healthcare Market Trends
  3. > Vision Care - Medical Devices Pipeline Assessment, 2016

Vision Care - Medical Devices Pipeline Assessment, 2016

  • December 2016
  • -
  • Global Data
  • -
  • 298 pages

Vision Care - Medical Devices Pipeline Assessment, 2016

Summary

GlobalData's Medical Devices sector report, “Vision Care - Medical Devices Pipeline Assessment, 2016" provides an overview of Vision Care currently in pipeline stage.

The report provides comprehensive information on the pipeline products with comparative analysis of the products at various stages of development. The report reviews major players involved in the pipeline product development. It also provides information about clinical trials in progress, which includes trial phase, trial status, trial start and end dates, and, the number of trials for the key Vision Care pipeline products.

This report is prepared using data sourced from in-house databases, secondary and primary research by GlobalData's team of industry experts.

*Note: Certain sections in the report may be removed or altered based on the availability and relevance of data in relation to the equipment type.

Scope

- Extensive coverage of the Vision Care under development
- The report reviews details of major pipeline products which includes, product description, licensing and collaboration details and other developmental activities
- The report reviews the major players involved in the development of Vision Care and list all their pipeline projects
- The coverage of pipeline products based on various stages of development ranging from Early Development to Approved / Issued stage
- The report provides key clinical trial data of ongoing trials specific to pipeline products
- Recent developments in the segment / industry

Reasons to buy

The report enables you to -
- Formulate significant competitor information, analysis, and insights to improve R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand important and diverse types of Vision Care under development
- Develop market-entry and market expansion strategies
- Plan mergers and acquisitions effectively by identifying major players with the most promising pipeline
- In-depth analysis of the product’s current stage of development, territory and estimated launch date

Table Of Contents

Vision Care - Medical Devices Pipeline Assessment, 2016
1 Table of Contents
1 Table of Contents 2
1.1 List of Tables 10
1.2 List of Figures 17
2 Introduction 18
2.1 Vision Care Overview 18
3 Products under Development 20
3.1 Vision Care - Pipeline Products by Stage of Development 20
3.2 Vision Care - Pipeline Products by Segment 21
3.3 Vision Care - Pipeline Products by Territory 22
3.4 Vision Care - Pipeline Products by Regulatory Path 23
3.5 Vision Care - Pipeline Products by Estimated Approval Date 24
3.6 Vision Care - Ongoing Clinical Trials 25
4 Vision Care - Pipeline Products under Development by Companies 26
4.1 Vision Care Companies - Pipeline Products by Stage of Development 26
4.2 Vision Care - Pipeline Products by Stage of Development 29
5 Vision Care Companies and Product Overview 33
5.1 Adventus Technology Inc Company Overview 33
5.1.1 Adventus Technology Inc Pipeline Products and Ongoing Clinical Trials Overview 33
5.2 Aeon Astron Corporation Company Overview 34
5.2.1 Aeon Astron Corporation Pipeline Products and Ongoing Clinical Trials Overview 34
5.3 Alcon, Inc. Company Overview 36
5.3.1 Alcon, Inc. Pipeline Products and Ongoing Clinical Trials Overview 36
5.4 Apeliotus Ophthalmics Company Overview 42
5.4.1 Apeliotus Ophthalmics Pipeline Products and Ongoing Clinical Trials Overview 42
5.5 Auburn University Company Overview 44
5.5.1 Auburn University Pipeline Products and Ongoing Clinical Trials Overview 44
5.6 Axcelon Biopolymers Corp. Company Overview 45
5.6.1 Axcelon Biopolymers Corp. Pipeline Products and Ongoing Clinical Trials Overview 45
5.7 Bar-Ilan University Company Overview 46
5.7.1 Bar-Ilan University Pipeline Products and Ongoing Clinical Trials Overview 46
5.8 Bausch and Lomb Inc Company Overview 47
5.8.1 Bausch and Lomb Inc Pipeline Products and Ongoing Clinical Trials Overview 47
5.9 Bionic Eye Technologies, Inc. Company Overview 50
5.9.1 Bionic Eye Technologies, Inc. Pipeline Products and Ongoing Clinical Trials Overview 50
5.10 Bionic Vision Australia Company Overview 51
5.10.1 Bionic Vision Australia Pipeline Products and Ongoing Clinical Trials Overview 51
5.11 Children's Hospital Boston Company Overview 54
5.11.1 Children's Hospital Boston Pipeline Products and Ongoing Clinical Trials Overview 54
5.12 Consejo Superior de Investigaciones Cientificas Company Overview 55
5.12.1 Consejo Superior de Investigaciones Cientificas Pipeline Products and Ongoing Clinical Trials Overview 55
5.13 CooperVision Inc Company Overview 56
5.13.1 CooperVision Inc Pipeline Products and Ongoing Clinical Trials Overview 56
5.14 Cornea Biosciences Company Overview 61
5.14.1 Cornea Biosciences Pipeline Products and Ongoing Clinical Trials Overview 61
5.15 Cornell University Company Overview 62
5.15.1 Cornell University Pipeline Products and Ongoing Clinical Trials Overview 62
5.16 EP Global Communications, Inc. Company Overview 63
5.16.1 EP Global Communications, Inc. Pipeline Products and Ongoing Clinical Trials Overview 63
5.17 eSight Corporation Company Overview 64
5.17.1 eSight Corporation Pipeline Products and Ongoing Clinical Trials Overview 64
5.18 Euclid Systems Corporation Company Overview 65
5.18.1 Euclid Systems Corporation Pipeline Products and Ongoing Clinical Trials Overview 65
5.19 Eyenovations Company Overview 66
5.19.1 Eyenovations Pipeline Products and Ongoing Clinical Trials Overview 66
5.20 EyeYon Medical Company Overview 67
5.20.1 EyeYon Medical Pipeline Products and Ongoing Clinical Trials Overview 67
5.21 iBionics Inc Company Overview 68
5.21.1 iBionics Inc Pipeline Products and Ongoing Clinical Trials Overview 68
5.22 Imperial College London Company Overview 70
5.22.1 Imperial College London Pipeline Products and Ongoing Clinical Trials Overview 70
5.23 iSTAR Medical SA Company Overview 71
5.23.1 iSTAR Medical SA Pipeline Products and Ongoing Clinical Trials Overview 71
5.24 John Hopkins University Company Overview 72
5.24.1 John Hopkins University Pipeline Products and Ongoing Clinical Trials Overview 72
5.25 Johnson and Johnson Vision Care Inc Company Overview 73
5.25.1 Johnson and Johnson Vision Care Inc Pipeline Products and Ongoing Clinical Trials Overview 73
5.26 Massachusetts Eye and Ear Infirmary Company Overview 75
5.26.1 Massachusetts Eye and Ear Infirmary Pipeline Products and Ongoing Clinical Trials Overview 75
5.27 McGill University Company Overview 76
5.27.1 McGill University Pipeline Products and Ongoing Clinical Trials Overview 76
5.28 Mercy Research and Development Company Overview 77
5.28.1 Mercy Research and Development Pipeline Products and Ongoing Clinical Trials Overview 77
5.29 Meta Biomed Co Ltd Company Overview 79
5.29.1 Meta Biomed Co Ltd Pipeline Products and Ongoing Clinical Trials Overview 79
5.30 Microbiosensor Ltd Company Overview 80
5.30.1 Microbiosensor Ltd Pipeline Products and Ongoing Clinical Trials Overview 80
5.31 Monash University Company Overview 81
5.31.1 Monash University Pipeline Products and Ongoing Clinical Trials Overview 81
5.32 Nano Retina, Inc. Company Overview 82
5.32.1 Nano Retina, Inc. Pipeline Products and Ongoing Clinical Trials Overview 82
5.33 Novartis AG Company Overview 83
5.33.1 Novartis AG Pipeline Products and Ongoing Clinical Trials Overview 83
5.34 Ocular Dynamics, LLC Company Overview 85
5.34.1 Ocular Dynamics, LLC Pipeline Products and Ongoing Clinical Trials Overview 85
5.35 Ocutec Ltd Company Overview 86
5.35.1 Ocutec Ltd Pipeline Products and Ongoing Clinical Trials Overview 86
5.36 PixelOptics Inc Company Overview 87
5.36.1 PixelOptics Inc Pipeline Products and Ongoing Clinical Trials Overview 87
5.37 Pixium Vision Company Overview 88
5.37.1 Pixium Vision Pipeline Products and Ongoing Clinical Trials Overview 88
5.38 Presbia Plc Company Overview 91
5.38.1 Presbia Plc Pipeline Products and Ongoing Clinical Trials Overview 91
5.39 Queensland University of Technology Company Overview 94
5.39.1 Queensland University of Technology Pipeline Products and Ongoing Clinical Trials Overview 94
5.40 Refocus Group Inc Company Overview 95
5.40.1 Refocus Group Inc Pipeline Products and Ongoing Clinical Trials Overview 95
5.41 RetMap Inc Company Overview 98
5.41.1 RetMap Inc Pipeline Products and Ongoing Clinical Trials Overview 98
5.42 ReVision Optics Inc Company Overview 99
5.42.1 ReVision Optics Inc Pipeline Products and Ongoing Clinical Trials Overview 99
5.43 Royal College of Surgeons in Ireland Company Overview 103
5.43.1 Royal College of Surgeons in Ireland Pipeline Products and Ongoing Clinical Trials Overview 103
5.44 Stanford University Company Overview 105
5.44.1 Stanford University Pipeline Products and Ongoing Clinical Trials Overview 105
5.45 Studio Oculistico Gualdi Company Overview 107
5.45.1 Studio Oculistico Gualdi Pipeline Products and Ongoing Clinical Trials Overview 107
5.46 Tel Aviv University Company Overview 108
5.46.1 Tel Aviv University Pipeline Products and Ongoing Clinical Trials Overview 108
5.47 The Hong Kong University of Science and Technology Company Overview 109
5.47.1 The Hong Kong University of Science and Technology Pipeline Products and Ongoing Clinical Trials Overview 109
5.48 The University of New South Wales Company Overview 110
5.48.1 The University of New South Wales Pipeline Products and Ongoing Clinical Trials Overview 110
5.49 UltraVision CLPL Company Overview 111
5.49.1 UltraVision CLPL Pipeline Products and Ongoing Clinical Trials Overview 111
5.50 University of Auckland Company Overview 112
5.50.1 University of Auckland Pipeline Products and Ongoing Clinical Trials Overview 112
5.51 University of California San Diego Company Overview 113
5.51.1 University of California San Diego Pipeline Products and Ongoing Clinical Trials Overview 113
5.52 University of Florida Company Overview 115
5.52.1 University of Florida Pipeline Products and Ongoing Clinical Trials Overview 115
5.53 University of Illinois at Chicago Company Overview 116
5.53.1 University of Illinois at Chicago Pipeline Products and Ongoing Clinical Trials Overview 116
5.54 University of Oxford Company Overview 118
5.54.1 University of Oxford Pipeline Products and Ongoing Clinical Trials Overview 118
5.55 University of South Florida Company Overview 119
5.55.1 University of South Florida Pipeline Products and Ongoing Clinical Trials Overview 119
5.56 University of Tennessee Company Overview 120
5.56.1 University of Tennessee Pipeline Products and Ongoing Clinical Trials Overview 120
5.57 University of Valencia Company Overview 121
5.57.1 University of Valencia Pipeline Products and Ongoing Clinical Trials Overview 121
5.58 University of Washington Company Overview 123
5.58.1 University of Washington Pipeline Products and Ongoing Clinical Trials Overview 123
5.59 Valeant Pharmaceuticals International Inc Company Overview 125
5.59.1 Valeant Pharmaceuticals International Inc Pipeline Products and Ongoing Clinical Trials Overview 125
5.60 Va-st Ltd Company Overview 139
5.60.1 Va-st Ltd Pipeline Products and Ongoing Clinical Trials Overview 139
5.61 Visioneering Technologies, Inc. Company Overview 140
5.61.1 Visioneering Technologies, Inc. Pipeline Products and Ongoing Clinical Trials Overview 140
5.62 VISTAKON Pharmaceuticals LLC Company Overview 144
5.62.1 VISTAKON Pharmaceuticals LLC Pipeline Products and Ongoing Clinical Trials Overview 144
5.63 Visus Technology, Inc. Company Overview 146
5.63.1 Visus Technology, Inc. Pipeline Products and Ongoing Clinical Trials Overview 146
5.64 Weill Cornell Medical College Company Overview 147
5.64.1 Weill Cornell Medical College Pipeline Products and Ongoing Clinical Trials Overview 147
5.65 Western University Company Overview 148
5.65.1 Western University Pipeline Products and Ongoing Clinical Trials Overview 148
5.66 Yolia Health Company Overview 150
5.66.1 Yolia Health Pipeline Products and Ongoing Clinical Trials Overview 150
5.67 ZircLight Inc. Company Overview 151
5.67.1 ZircLight Inc. Pipeline Products and Ongoing Clinical Trials Overview 151
6 Vision Care- Recent Developments 153
6.1 Nov 16, 2016: New Head of the ZEISS Semiconductor Manufacturing Technology Business Group 153
6.2 Nov 10, 2016: Alcon introduces new AIR OPTIX plus HydraGlyde monthly replacement contact lenses at the American Academy of Optometry annual meeting 154
6.3 Nov 10, 2016: ReVision Optics Raises USD32 Million in Venture Financing 154
6.4 Nov 10, 2016: NovaBay Pharmaceuticals Reports 2016 Third Quarter Financial Results 155
6.5 Nov 09, 2016: University of Melbourne and National Vision Research Institute of Australia win $1 M grant to develop diamond bionic eye prototype 156
6.6 Nov 09, 2016: New Study Shows Groundbreaking Contact Lens Therapy Effective in Slowing Myopia Progression in Children by 59% Over Two Years 157
6.7 Nov 09, 2016: Daniel B. Polley, Ph.D., appointed Director of Lauer Tinnitus Research Center at Mass. Eye and Ear 159
6.8 Nov 08, 2016: Valeant Reports Third Quarter 2016 Financial Results 159
6.9 Nov 07, 2016: Pixium Vision announces the first successful implantation and activation of IRIS II, 150 electrode bionic vision system, in the UK 162
6.10 Nov 07, 2016: TearLab Reports Third Quarter and September Year-To-Date 2016 Financial Results 164
6.11 Nov 03, 2016: STAAR Surgical Reports Third Quarter 2016 Results 164
6.12 Oct 28, 2016: Hoya Reports Second Quarter Results 165
6.13 Oct 27, 2016: VTI Introduces the NaturalVue Multifocal QuickStart Calculator 166
6.14 Oct 26, 2016: ZEISS Invests Further 60 Million Euros in the Expansion of the Semiconductor Manufacturing Technology Factory 166
6.15 Oct 26, 2016: Edmund Optics and Varioptic Announce the Availability of the Variable Focus Arctic Liquid Lens in the EO Catalog 167
6.16 Oct 25, 2016: Novartis delivered solid third quarter with Growth Products offsetting Gleevec patent expiration; several positive readouts for potential blockbusters 167
6.17 Oct 21, 2016: Essilor: Nine-Month Consolidated Revenue up 7.8% at Constant Exchange Rates 174
6.18 Oct 20, 2016: CollPlant Files Registration Statement to Raise up to USD25 Million in IPO 176
6.19 Oct 18, 2016: LumiThera to Raise USD5 Million in Venture Financing 176
6.20 Oct 17, 2016: Wearable Artificial Vision Device Shows Promise in Helping People Who Are Legally Blind "Read" 176
6.21 Oct 13, 2016: Carl Zeiss Meditec appoints Steven C. Schallhorn, MD as Chief Medical Officer 177
6.22 Oct 12, 2016: Hoya to Acquire Performance Optics for up to USD476 Million 178
6.23 Oct 06, 2016: Valeant Appoints Louis W. Yu, Ph.D. As Chief Quality Officer 178
6.24 Sep 27, 2016: Orange County Business Council Study Showcases Economic Impact of Allergan on California Economy 179
6.25 Sep 16, 2016: Johnson and Johnson to Acquire Abbott Medical Optics from Abbott Laboratories for USD4.32 Billion 180
6.26 Sep 15, 2016: PFO Global Raises USD0.4 Million in Private Placement of Debenture 180
6.27 Sep 13, 2016: Novartis Raises USD561.78 Million in Public Offering of International Bonds Due 2028 181
6.28 Sep 13, 2016: Novartis Raises USD1.40 Billion in Public Offering of International Bonds Due 2023 181
6.29 Sep 12, 2016: Pixium Vision receives clinical trial approval from Spanish Ministry of Health for 150 electrode IRIS II bionic vision system 181
6.30 Sep 09, 2016: KKR Invests USD66 Million in AcuFocus 182
6.31 Sep 01, 2016: The Cooper Companies CFO Gregory W. Matz to Retire; Albert G. White Named Successor in Planned Transition 182
6.32 Sep 01, 2016: The Cooper Companies Announces Third Quarter 2016 Results 182
6.33 Aug 31, 2016: ReVision Optics Announces First U.S. Commercial Cases of Raindrop Near Vision Inlay 183
6.34 Aug 30, 2016: FDA-Approved Raindrop Near Vision Inlay Corrects Blurry Reading Vision -- Now Available in Utah for the First Time 184
6.35 Aug 29, 2016: Drug-dispensing contact lens effectively lowers eye pressure in pre-clinical glaucoma model 184
6.36 Aug 29, 2016: Drug Dispensing Contact lens Effectively Lowers Eye Pressure in Pre clinical Glaucoma Model 185
6.37 Aug 22, 2016: Valeant Pharmaceuticals Appoints Paul S. Herendeen As Executive Vice President, Finance And Chief Financial Officer 186
6.38 Aug 18, 2016: ReVision Optics Secures USD10 Million from Square 1 Bank 187
6.39 Aug 18, 2016: Luiz de Freitas Joins VISION EASE as Commercial Director for Mexico 187
6.40 Aug 15, 2016: CooperVision Unveils Avaira Vitality Sphere and Toric Two-Week Contact Lenses 188
6.41 Aug 12, 2016: Carl Zeiss Meditec Grows in Ophthalmology and Microsurgery 189
6.42 Aug 11, 2016: Outcomes of Presbia Microlens Surgeries in Korean Study Demonstrate Excellent Results 189
6.43 Aug 11, 2016: NovaBay Pharmaceuticals Reports 2016 Second Quarter Financial Results 190
6.44 Aug 10, 2016: ReVision Optics Names Dr. Nick J. Manesis Vice President of RandD 191
6.45 Aug 10, 2016: Acufocus Raises USD2 Million in Venture Financing 192
6.46 Aug 10, 2016: Valeant Pharmaceuticals Comments On SDNY Investigation 192
6.47 Aug 09, 2016: Valeant Pharmaceuticals Reports Second Quarter 2016 Financial Results 192
6.48 Aug 08, 2016: Valeant Pharmaceuticals Announces Changes To Executive Management Team 194
6.49 Aug 03, 2016: STAAR Surgical Reports Second Quarter 2016 Results 195
6.50 Aug 03, 2016: TearLab Reports Second Quarter and June Year-To-Date 2016 Financial Results 197
6.51 Aug 01, 2016: Study Shows Corneal Structural Changes Induced by ReVision Optics' Raindrop Near Vision Inlay Significantly Improve Near and Intermediate Vision in Subjects with Presbyopia 197
6.52 Aug 01, 2016: NovaBay Pharma Raises USD4 Million in Second and Final Tranche of Private Placement of Units 198
6.53 Aug 01, 2016: Essilor International: Improving Lives by Improving Sight 199
6.54 Jul 29, 2016: Essilor - First-Half 2016 Results: Revenue Up 8.1% Excluding the Currency Effect 200
6.55 Jul 29, 2016: Hoya Reports First Quarter Financial Results 203
6.56 Jul 28, 2016: Valeant Pharmaceuticals Announces The Addition Of Sarah B. Kavanagh To Its Board Of Directors 204
6.57 Jul 27, 2016: Carl Zeiss Meditec Recruits James V. Mazzo to Lead Its Newly Consolidated Ophthalmology Organization 204
6.58 Jul 25, 2016: Pixium Vision Announces CE Mark Approval of IRIS II, Its First Bionic Vision System 205
6.59 Jul 25, 2016: ReVision Optics Appoints Frank Shields Vice President of Sales Worldwide 206
6.60 Jul 20, 2016: Pixium Vision First Half 2016 Financial Results and Business Update 206
6.61 Jul 20, 2016: Carl Zeiss Meditec announces change to Management Board 208
6.62 Jul 19, 2016: Novartis delivered solid Q2 despite full quarter of US Gleevec generic impact; significant positive innovation news strengthens future growth prospects 208
6.63 Jul 18, 2016: Combined Cataract and Presbia Microlens Surgeries Demonstrate Excellent Results and Patient Satisfaction in Near-Vision Improvement 214
6.64 Jul 14, 2016: Alcon launches Dailies Total1 Multifocal contact lenses, the first and only water gradient lenses designed for people with presbyopia 214
6.65 Jul 14, 2016: China Grand Pharma Raises USD22 Million in Private Placement of Shares 215
6.66 Jul 11, 2016: Presbia to Participate in the 2016 Australasian Society of Cataract and Refractive Surgeons 20th Annual Conference 215
6.67 Jul 07, 2016: Allergan Demonstrates a Strong Commitment to America's First Responders Donating Over $1 Million Worth of REFRESH Eye Drops 216
6.68 Jul 06, 2016: U.S. patent trial and appeal board grants ZEISS' petition and institutes IPR against NPE patent holder AMI 216
6.69 Jul 06, 2016: Rayner Continues Growth in Europe with Direct Presence in Italy 217
7 Appendix 295
7.1 Methodology 295
7.2 About GlobalData 297
7.3 Contact Us 298
7.4 Disclaimer 298

1.1
List of Tables

Table 1: Vision Care - Pipeline Products by Stage of Development 20
Table 2: Vision Care - Pipeline Products by Segment 21
Table 3: Vision Care - Pipeline Products by Territory 22
Table 4: Vision Care - Pipeline Products by Regulatory Path 23
Table 5: Vision Care - Pipeline Products by Estimated Approval Date 24
Table 6: Vision Care - Ongoing Clinical Trials 25
Table 7: Vision Care Companies - Pipeline Products by Stage of Development 26
Table 8: Vision Care - Pipeline Products by Stage of Development 29
Table 9: Adventus Technology Inc Pipeline Products and Ongoing Clinical Trials Overview 33
Table 10: Corneal Onlay - Product Status 33
Table 11: Corneal Onlay - Product Description 33
Table 12: Aeon Astron Corporation Pipeline Products and Ongoing Clinical Trials Overview 34
Table 13: Biolens - Product Status 34
Table 14: Biolens - Product Description 34
Table 15: Body Organ Contact Lens - Product Status 35
Table 16: Body Organ Contact Lens - Product Description 35
Table 17: Alcon, Inc. Pipeline Products and Ongoing Clinical Trials Overview 36
Table 18: AIR OPTIX Plus HydraGlyde Monthly Replacement Clear And Color Lens - Product Status 36
Table 19: AIR OPTIX Plus HydraGlyde Monthly Replacement Clear And Color Lens - Product Description 37
Table 20: AIR OPTIX Plus HydraGlyde Monthly Replacement Contact Lenses - Product Status 37
Table 21: AIR OPTIX Plus HydraGlyde Monthly Replacement Contact Lenses - Product Description 37
Table 22: AIR OPTIX Plus HydraGlyde Monthly Replacement Multifocal Lens - Product Status 38
Table 23: AIR OPTIX Plus HydraGlyde Monthly Replacement Multifocal Lens - Product Description 38
Table 24: AIR OPTIX Plus HydraGlyde Monthly Replacement Toric Lens - Product Status 39
Table 25: AIR OPTIX Plus HydraGlyde Monthly Replacement Toric Lens - Product Description 39
Table 26: Dailies Total 1 Colors SiHy Lens - Product Status 39
Table 27: Dailies Total 1 Colors SiHy Lens - Product Description 40
Table 28: Dailies Total 1 Toric SiHy Lens - Product Status 40
Table 29: Dailies Total 1 Toric SiHy Lens - Product Description 40
Table 30: Smart Lens - Diabetes - Product Status 41
Table 31: Smart Lens - Diabetes - Product Description 41
Table 32: Weekly WG SiHy Lens - Product Status 41
Table 33: Weekly WG SiHy Lens - Product Description 42
Table 34: Apeliotus Ophthalmics Pipeline Products and Ongoing Clinical Trials Overview 42
Table 35: Comfort Lens - Product Status 42
Table 36: Comfort Lens - Product Description 43
Table 37: Contact Lens - Glaucoma - Product Status 43
Table 38: Contact Lens - Glaucoma - Product Description 43
Table 39: Auburn University Pipeline Products and Ongoing Clinical Trials Overview 44
Table 40: Smart Contact Lenses - Product Status 44
Table 41: Smart Contact Lenses - Product Description 44
Table 42: Axcelon Biopolymers Corp. Pipeline Products and Ongoing Clinical Trials Overview 45
Table 43: MC - PHEMA Based Contact Lens - Product Status 45
Table 44: MC - PHEMA Based Contact Lens - Product Description 45
Table 45: Bar-Ilan University Pipeline Products and Ongoing Clinical Trials Overview 46
Table 46: Bionic Contact Lens - Product Status 46
Table 47: Bionic Contact Lens - Product Description 46
Table 48: Bausch and Lomb Inc Pipeline Products and Ongoing Clinical Trials Overview 47
Table 49: Ultra Plus Powers Lens - Product Status 47
Table 50: Ultra Plus Powers Lens - Product Description 48
Table 51: Ultra Toric Lens - Product Status 48
Table 52: Ultra Toric Lens - Product Description 49
Table 53: Bionic Eye Technologies, Inc. Pipeline Products and Ongoing Clinical Trials Overview 50
Table 54: Retinal Prosthesis System - Product Status 50
Table 55: Retinal Prosthesis System - Product Description 50
Table 56: Bionic Vision Australia Pipeline Products and Ongoing Clinical Trials Overview 51
Table 57: High-Acuity Device With 1024 Electrodes - Product Status 51
Table 58: High-Acuity Device With 1024 Electrodes - Product Description 51
Table 59: Wide-View Device With 24-channel - Product Status 52
Table 60: Wide-View Device With 24-channel - Product Description 52
Table 61: Wide-View Device With 44-channel - Product Status 52
Table 62: Wide-View Device With 44-channel - Product Description 53
Table 63: Wide-View Device With 98 Electrodes - Product Status 53
Table 64: Wide-View Device With 98 Electrodes - Product Description 53
Table 65: Children's Hospital Boston Pipeline Products and Ongoing Clinical Trials Overview 54
Table 66: Contact Lens Drug Delivery Device - Product Status 54
Table 67: Contact Lens Drug Delivery Device - Product Description 54
Table 68: Consejo Superior de Investigaciones Cientificas Pipeline Products and Ongoing Clinical Trials Overview 55
Table 69: Reduced Optical Instrument - Product Status 55
Table 70: Reduced Optical Instrument - Product Description 55
Table 71: CooperVision Inc Pipeline Products and Ongoing Clinical Trials Overview 56
Table 72: Biofinity Energys - Product Status 56
Table 73: Biofinity Energys - Product Description 57
Table 74: MiSight Dual-Focus Myopia Control 1-Day Soft Contact Lens - Product Status 57
Table 75: MiSight Dual-Focus Myopia Control 1-Day Soft Contact Lens - Product Description 58
Table 76: SiH Multifocal - Product Status 58
Table 77: SiH Multifocal - Product Description 58
Table 78: CooperVision Inc - Ongoing Clinical Trials Overview 59
Table 79: MiSight Dual-Focus Myopia Control 1-Day Soft Contact Lens - A Multi-center Dispensing Clinical Evaluation of MiSight Lenses 60
Table 80: MiSight Dual-Focus Myopia Control 1-Day Soft Contact Lens - Efficacy and Safety of MiSight Contact Lenses in Reducing the Progression of Childhood Myopia, Not Pathological, Aged 8-12 Years Randomized Clinical Trial 60
Table 81: Cornea Biosciences Pipeline Products and Ongoing Clinical Trials Overview 61
Table 82: Bioengineered Cornea - Product Status 61
Table 83: Bioengineered Cornea - Product Description 61
Table 84: Cornell University Pipeline Products and Ongoing Clinical Trials Overview 62
Table 85: Prosthetic Retinal Device - Product Status 62
Table 86: Prosthetic Retinal Device - Product Description 62
Table 87: EP Global Communications, Inc. Pipeline Products and Ongoing Clinical Trials Overview 63
Table 88: EP Global Contact Lens - Product Status 63
Table 89: EP Global Contact Lens - Product Description 63
Table 90: eSight Corporation Pipeline Products and Ongoing Clinical Trials Overview 64
Table 91: evSpex - Product Status 64
Table 92: evSpex - Product Description 64
Table 93: Euclid Systems Corporation Pipeline Products and Ongoing Clinical Trials Overview 65
Table 94: Drug-Eluting Contact Lenses - Product Status 65
Table 95: Drug-Eluting Contact Lenses - Product Description 65
Table 96: Eyenovations Pipeline Products and Ongoing Clinical Trials Overview 66
Table 97: Drug Dispensing Contact Lens - Product Status 66
Table 98: Drug Dispensing Contact Lens - Product Description 66
Table 99: EyeYon Medical Pipeline Products and Ongoing Clinical Trials Overview 67
Table 100: DSPEK - Product Status 67
Table 101: DSPEK - Product Description 67
Table 102: iBionics Inc Pipeline Products and Ongoing Clinical Trials Overview 68
Table 103: iBIONICS Diamond Eye - Product Status 68
Table 104: iBIONICS Diamond Eye - Product Description 69
Table 105: Imperial College London Pipeline Products and Ongoing Clinical Trials Overview 70
Table 106: Contact Lens - Product Status 70
Table 107: Contact Lens - Product Description 70
Table 108: iSTAR Medical SA Pipeline Products and Ongoing Clinical Trials Overview 71
Table 109: STARvue - Product Status 71
Table 110: STARvue - Product Description 71
Table 111: John Hopkins University Pipeline Products and Ongoing Clinical Trials Overview 72
Table 112: Intra-corneal Implant - Product Status 72
Table 113: Intra-corneal Implant - Product Description 72
Table 114: Johnson and Johnson Vision Care Inc Pipeline Products and Ongoing Clinical Trials Overview 73
Table 115: 1-DAY ACUVUE Multifocal Contact Lens - Product Status 73
Table 116: 1-DAY ACUVUE Multifocal Contact Lens - Product Description 73
Table 117: Anti-allergic Contact Lens - Product Status 74
Table 118: Anti-allergic Contact Lens - Product Description 74
Table 119: Massachusetts Eye and Ear Infirmary Pipeline Products and Ongoing Clinical Trials Overview 75
Table 120: Therapeutic Contact Lens - Product Status 75
Table 121: Therapeutic Contact Lens - Product Description 75
Table 122: McGill University Pipeline Products and Ongoing Clinical Trials Overview 76
Table 123: Portable System - Amblyopia - Product Status 76
Table 124: Portable System - Amblyopia - Product Description 76
Table 125: Mercy Research and Development Pipeline Products and Ongoing Clinical Trials Overview 77
Table 126: First Aid Lens - Product Status 77
Table 127: First Aid Lens - Product Description 77
Table 128: Healing Lens - Product Status 78
Table 129: Healing Lens - Product Description 78
Table 130: Meta Biomed Co Ltd Pipeline Products and Ongoing Clinical Trials Overview 79
Table 131: Artificial Cornea - Product Status 79
Table 132: Artificial Cornea - Product Description 79
Table 133: Microbiosensor Ltd Pipeline Products and Ongoing Clinical Trials Overview 80
Table 134: MicroBioSensor-Contact Lens - Product Status 80
Table 135: MicroBioSensor-Contact Lens - Product Description 80
Table 136: Monash University Pipeline Products and Ongoing Clinical Trials Overview 81
Table 137: Monash Vision - Product Status 81
Table 138: Monash Vision - Product Description 81
Table 139: Nano Retina, Inc. Pipeline Products and Ongoing Clinical Trials Overview 82
Table 140: NR600 Implant - Product Status 82
Table 141: NR600 Implant - Product Description 82
Table 142: Novartis AG Pipeline Products and Ongoing Clinical Trials Overview 83
Table 143: CLM041 - Product Status 83
Table 144: CLM041 - Product Description 84
Table 145: Ocular Dynamics, LLC Pipeline Products and Ongoing Clinical Trials Overview 85
Table 146: Contact Lens - Dry Eye Disease - Product Status 85
Table 147: Contact Lens - Dry Eye Disease - Product Description 85
Table 148: Ocutec Ltd Pipeline Products and Ongoing Clinical Trials Overview 86
Table 149: Third PEG Hydrogel Contact Lens - Product Status 86
Table 150: Third PEG Hydrogel Contact Lens - Product Description 86
Table 151: PixelOptics Inc Pipeline Products and Ongoing Clinical Trials Overview 87
Table 152: Behold - Product Status 87
Table 153: Behold - Product Description 87
Table 154: Pixium Vision Pipeline Products and Ongoing Clinical Trials Overview 88
Table 155: IRIS II Bionic Vision System - Product Status 88
Table 156: IRIS II Bionic Vision System - Product Description 89
Table 157: PRIMA - Product Status 89
Table 158: PRIMA - Product Description 90
Table 159: Presbia Plc Pipeline Products and Ongoing Clinical Trials Overview 91
Table 160: Presbia Flexivue Microlens - Product Status 91
Table 161: Presbia Flexivue Microlens - Product Description 91
Table 162: Presbia Plc - Ongoing Clinical Trials Overview 92
Table 163: Presbia Flexivue Microlens - A Phase II trial of Presbia Flexivue Microlens for The Treatment of Presbyopia 93
Table 164: Presbia Flexivue Microlens - Prospective, Non-randomized, Unmasked, Multicenter Clinical Investigation of the Presbia Flexivue Microlens for the Improvement of Near Vision in Emmetropic Presbyopes 93
Table 165: Queensland University of Technology Pipeline Products and Ongoing Clinical Trials Overview 94
Table 166: Ophthalmic Lenses - Product Status 94
Table 167: Ophthalmic Lenses - Product Description 94
Table 168: Refocus Group Inc Pipeline Products and Ongoing Clinical Trials Overview 95
Table 169: VisAbility Implant System - Product Status 95
Table 170: VisAbility Implant System - Product Description 95
Table 171: Refocus Group Inc - Ongoing Clinical Trials Overview 96
Table 172: VisAbility Implant System - A Prospective, Multicenter Clinical Trial of the VisAbility Implant System for Improvement of Near Visual Acuity in Presbyopic Patients 97
Table 173: RetMap Inc Pipeline Products and Ongoing Clinical Trials Overview 98
Table 174: CLEAr Lens - Product Status 98
Table 175: CLEAr Lens - Product Description 98
Table 176: ReVision Optics Inc Pipeline Products and Ongoing Clinical Trials Overview 99
Table 177: Raindrop Near Vision Inlay - Product Status 99
Table 178: Raindrop Near Vision Inlay - Product Description 100
Table 179: ReVision Optics Inc - Ongoing Clinical Trials Overview 101
Table 180: Raindrop Near Vision Inlay - A Prospective, Multicenter Clinical Trial to Evaluate the Safety and Effectiveness of the ReVision Optics, Inc., Raindrop Near Vision Inlay for the Improvement of Near and Intermediate Vision in Pseudophakic Subjects 102
Table 181: Royal College of Surgeons in Ireland Pipeline Products and Ongoing Clinical Trials Overview 103
Table 182: OcularColl - Product Status 103
Table 183: OcularColl - Product Description 104
Table 184: Stanford University Pipeline Products and Ongoing Clinical Trials Overview 105
Table 185: Biological Neural Network Based Retinal Prosthesis - Product Status 105
Table 186: Biological Neural Network Based Retinal Prosthesis - Product Description 106
Table 187: Polymer Network Hydrogel Contact Lens - Product Status 106
Table 188: Polymer Network Hydrogel Contact Lens - Product Description 106
Table 189: Studio Oculistico Gualdi Pipeline Products and Ongoing Clinical Trials Overview 107
Table 190: PEARL Inlay - Product Status 107
Table 191: PEARL Inlay - Product Description 107
Table 192: Tel Aviv University Pipeline Products and Ongoing Clinical Trials Overview 108
Table 193: Bionic Eye - Product Status 108
Table 194: Bionic Eye - Product Description 108
Table 195: The Hong Kong University of Science and Technology Pipeline Products and Ongoing Clinical Trials Overview 109
Table 196: Resonance Circuit Sensor Contact Lens - Product Status 109
Table 197: Resonance Circuit Sensor Contact Lens - Product Description 109
Table 198: The University of New South Wales Pipeline Products and Ongoing Clinical Trials Overview 110
Table 199: Stem Cell Contact Lens - Product Status 110
Table 200: Stem Cell Contact Lens - Product Description 110
Table 201: UltraVision CLPL Pipeline Products and Ongoing Clinical Trials Overview 111
Table 202: Contact Lenses - Product Status 111
Table 203: Contact Lenses - Product Description 111
Table 204: University of Auckland Pipeline Products and Ongoing Clinical Trials Overview 112
Table 205: Vision Screening System - Product Status 112
Table 206: Vision Screening System - Product Description 112
Table 207: University of California San Diego Pipeline Products and Ongoing Clinical Trials Overview 113
Table 208: Aerated Contact Lens - Product Status 113
Table 209: Aerated Contact Lens - Product Description 113
Table 210: Telescopic Contact Lens - Product Status 114
Table 211: Telescopic Contact Lens - Product Description 114
Table 212: University of Florida Pipeline Products and Ongoing Clinical Trials Overview 115
Table 213: Vitamin E - Packed Lenses - Product Status 115
Table 214: Vitamin E - Packed Lenses - Product Description 115
Table 215: University of Illinois at Chicago Pipeline Products and Ongoing Clinical Trials Overview 116
Table 216: Keratoprosthesis - Product Status 116
Table 217: Keratoprosthesis - Product Description 116
Table 218: Transcorneal Telescope - Product Status 117
Table 219: Transcorneal Telescope - Product Description 117

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Veronica

+1 718 514 2762

Purchase Reports From Reputable Market Research Publishers
Gastric Cancer Therapeutics in Asia-Pacific Markets to 2022 - Growth Driven by Increasing Prevalence and Launch of Targeted Therapies

Gastric Cancer Therapeutics in Asia-Pacific Markets to 2022 - Growth Driven by Increasing Prevalence and Launch of Targeted Therapies

  • $ 4995
  • Industry report
  • September 2016
  • by GBI Research

Gastric Cancer Therapeutics in Asia-Pacific Markets to 2022 - Growth Driven by Increasing Prevalence and Launch of Targeted Therapies Summary Gastric cancer is characterized by the formation of malignant ...

Global Cardiovascular Disease Market to 2022 - Sanofi and Novartis to Become Market Leaders as Praluent and Entresto Drive Revenue Growth

Global Cardiovascular Disease Market to 2022 - Sanofi and Novartis to Become Market Leaders as Praluent and Entresto Drive Revenue Growth

  • $ 4995
  • Industry report
  • October 2016
  • by GBI Research

Global Cardiovascular Disease Market to 2022 - Sanofi and Novartis to Become Market Leaders as Praluent and Entresto Drive Revenue Growth Summary Cardiovascular disease (CVD) covers a range of difference ...

Hemophilia A and B Therapeutics in Asia-Pacific Markets to 2022 - Growth Driven by Increasing Treatment-Receiving Pool, Launch of Long-Acting Replacement Therapies and Non-factor Therapy

Hemophilia A and B Therapeutics in Asia-Pacific Markets to 2022 - Growth Driven by Increasing Treatment-Receiving Pool, Launch of Long-Acting Replacement Therapies and Non-factor Therapy

  • $ 4995
  • Industry report
  • November 2016
  • by GBI Research

Hemophilia A and B Therapeutics in Asia-Pacific Markets to 2022 - Growth Driven by Increasing Treatment-Receiving Pool, Launch of Long-Acting Replacement Therapies and Non-factor Therapy Summary Hemophilia ...


ref:plp2016

Reportlinker.com © Copyright 2016. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.